Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

However, while Wegovy is prescribed by the NHS for weight management, Rybelsus is not licensed for such and is only available as a treatment for Type 2 diabetes. There are other limitations too. In ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

These drugs, developed for type 2 diabetes, also help in weight loss. They include the drug liraglutide, under the name ...